Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04428918|
Recruitment Status : Withdrawn (The study was closed due to investigator discretion based on the lack of ability to recruit patients and research goals of the program.)
First Posted : June 11, 2020
Last Update Posted : September 22, 2020
Allogenic hematopoietic cell transplantation (HCT) is a procedure in which a person gets stem cells from a donor in order to treat their disease. Researchers want to collect samples from people who have had or will have HCT. They will perform tests on the samples to study the immune system and its response to infections and disease.
To collect biological samples from people who have had or are planning to have HCT to treat primary immunodeficiencies, blood cancers, or disorders of T-cell proliferation and/or dysregulation.
People age 8 years and older who have undergone or are planning to undergo HCT.
Participants will be screened with:
Medical chart review
Participants may give blood and urine samples.
Participants may have a skin biopsy.
Participants may undergo apheresis. For this, a needle will be placed into an arm vein to take blood. A machine divides the whole blood into parts. The sample cells are taken out and the rest of the blood is returned through a second needle in the other arm.
Participants may have a bone marrow aspiration and biopsy. For this, the hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.
Participants may have a tumor or other abnormal tissue biopsy. For this, a tissue sample is obtained using a needle and syringe. They will sign a separate consent form. They may have a body scan or ultrasound to help locate the tumor during the biopsy.
Participation lasts for as long as participants choose to give samples.
|Condition or disease|
|Hematopoietic Stem Cell Transplantation Cell Transplantation Hematologic Malignancies|
- Allogenic Hematopoietic Cell Transplantation (HCT) is a potentially curative option for some patients with primary immunodeficiencies (PID) and hematological cancers.
- HCT for PID looks to restore defects in cells of hematopoietic origin allowing for eradication of protracted or recurrent viral infections.
- The curative potential of allogenic HCT for hematologic malignancies is mediated by the allogeneic immune system through a graft-versus-tumor (GVT) effect.
- Characterization of the immunologic landscape in patients with successful eradication of viral infections and hematologic malignancies following allogenic HCT requires further investigation.
-To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens from patients with allogenic HCT and perform immunological landscape studies.
-Patients age greater than or equal to 8 years of age and have undergone or are planning to undergo HCT.
- Up to 100 subjects will be enrolled.
- Patients may undergo sampling of blood, apheresis products, tumor, effusions, ascites, urine, bone marrow, skin, mucosa, saliva, stool, sputum, spinal fluid, or other tissues or fluids for banking and laboratory studies.
- No investigational or experimental therapy will be given as part of this protocol.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation|
|Actual Study Start Date :||June 5, 2020|
|Actual Primary Completion Date :||September 17, 2020|
|Actual Study Completion Date :||September 17, 2020|
Allogeneic HCT recipient or patient pending receipt of HCT
- Sample Aquisition [ Time Frame: Ongoing ]To conduct immunological landscape studies on samples collected. To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens from patients with allogenic HCT.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04428918
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Christian S Hinrichs, M.D.||National Cancer Institute (NCI)|